~~<i id='AA34A403E8'><strike id='AA34A403E8'><tt id='AA34A403E8'><pre id='AA34A403E8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：focus 2025-09-29 12:09:29 - browse：6465

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Nearly two

focus

entertainment

focus

leisure time

Wikipedia

AdobeThere’sampleevidencethatprivateequitybuyoutsinhealthcaredriveupcosts.Anewstudyshowsqualitydecli

WSS

Readout Newsletter: The latest on Moderna, Apellis, and Merck

ER docs worry over extreme heat as a 'mass casualty event'

What STAT readers think about the FDA and patient advocacy

A cyberattack has disrupted hospitals and health care in several states

Medicare Advantage beneficiaries sue Humana over algorithm use

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

knowledge

focus

The cancer drug shortage isn’t new — and neither are the solutions

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Cancer drug shortages should be causing more outrage

Readout Newsletter: The latest on Moderna, Apellis, and Merck

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why health care costs have stayed mostly flat since 2010

Hollywood unions extend contract negotiations for actors

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Moonlake's readout produced a cash windfall. Risks remain

Keeping primary care docs in field isn't impossible, says AAFP CEO

entertainment

Virtual care provider acquires bankrupt Pear's prescription apps

White House drug shortage group privately met with industry

Influencer to be charged after chaos erupts in New York City's Union Square

Dramatically reducing cancer deaths requires the PASTEUR Act

Attacks on the drug industry will lead to fewer breakthroughs

Stem cell clinics for heart failure: buyer be wary

focus

focus

leisure time

Wikipedia